Francis Aniekwensi, MD
Family Medicine · Henderson, NCNPI 1316054364
Payments from drug & device makers
Across 71 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$234
- Lilly USA, LLC$113
- Amarin Pharma, Inc.$97
- Exact Sciences$96
- Pfizer$87
- Johnson & Johnson$80
- plus $458 from 17 others
What the payments were for
- Food & beverage$1,165100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $234 |
| Lilly USA, LLC | 6 | $113 |
| Amarin Pharma, Inc. | 7 | $97 |
| Exact Sciences | 5 | $96 |
| Pfizer | 6 | $87 |
| Johnson & Johnson | 5 | $80 |
| Novo Nordisk | 4 | $75 |
| Amgen | 4 | $58 |
| Global Blood Therapeutics, Inc. | 3 | $47 |
| Merck | 2 | $33 |
| Gilead | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Medtronic | 1 | $25 |
| Insulet Corporation | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $20 |
| UCB, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| AstraZeneca | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Novartis | 1 | $12 |
| Cashflow Solutions, LLC | 1 | $10 |
How this compares
$1,165 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 170 | $172,784 |
| JanuviaSitagliptin Phosphate | 77 | $78,147 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $60,486 |
| EliquisApixaban | 72 | $60,179 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $42,698 |
| XareltoRivaroxaban | 46 | $37,644 |
| FarxigaDapagliflozin Propanediol | 31 | $37,200 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $26,771 |
| MounjaroTirzepatide | 20 | $21,328 |
| LinzessLinaclotide | 27 | $17,479 |
| JardianceEmpagliflozin | 21 | $17,026 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $15,973 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $13,746 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $12,667 |
| EntrestoSacubitril/Valsartan | 14 | $12,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $75 | $172,784170 claims |
| MerckJanuvia, Janumet | $33 | $94,12093 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $234 | $87,257143 claims |
| PfizerEliquis | $87 | $60,17972 claims |
| AstraZenecaFarxiga, Symbicort | $15 | $50,94677 claims |
| Johnson & JohnsonXarelto | $80 | $37,64446 claims |
| Lilly USA, LLCMounjaro | $113 | $21,32820 claims |
| NovartisEntresto | $12 | $12,54014 claims |
| Hikma Pharmaceuticals USAMitigare | $15 | $5,96911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Henderson
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.